Peptide LibraryGHRP-1
GHRP-1 is a growth hormone-releasing peptide in the Growth Hormone Secretagogue class. GHRP-1 is a synthetic enkephalin-derived peptide that binds the growth hormone secretagogue receptor 1a on pituitary somatotrophs and hypothalamic neurons, the receptor for ghrelin. Activation stimulates pulsatile growth hormone release through a pathway distinct from and synergistic with growth hormone-releasing hormone.
For research use only.
Key Facts
- CAS
- 141925-59-9
- Molecular Weight (MW)
- 955.1 g/mol
- Half-life
- —
- FDA status
- Not Approved
- Evidence level
- Limited Human Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
Research summary
Synthetic hexapeptide growth hormone secretagogue from the same series as GHRP-2 and GHRP-6. Not FDA-approved and less studied than either. Human pharmacokinetic data is limited.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trials2 reviewed sources
- Early or uncontrolled human studiesOnly in 1 review or summary
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's GHRP-1 profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
GHRP-1 dosage: no established human dose
GHRP-1 has no established human dosage. The human studies used it as a single intravenous test dose to provoke growth hormone release: 1 mcg/kg in children with growth hormone deficiency, and a 100 mcg bolus in nonpregnant and postpartum women. No trial has tested repeated doses or any injection under the skin.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: GHRP-1 is a synthetic seven-amino-acid peptide that acts on the ghrelin receptor and releases growth hormone. Its human use is limited to research and diagnostic studies from the 1990s that gave a single intravenous dose and measured the growth hormone response. Most other published work is in animals (for example lambs) or on cells, and no product containing it has been approved.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established; studied only as a single intravenous bolus in the reviewed abstracts |
| Evidence level | Limited Human Evidence |
| Last reviewed | 2026-11-07 |
Human research reported
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Growth hormone-deficient children (1995)Clinical trial · Randomized-order endocrine test study | Prepubertal children with growth hormone deficiency (n=22) | 1 mcg/kg, alone or with 1 mcg/kg GHRH | Intravenous | Single test dose, tests at least 1 week apart | Acute | 60% had a significant growth hormone response, similar to GHRH; the two together acted synergistically | Growth hormone (GH) responses to GH-releasing peptide and to GH-releasing hormone in GH-deficient children. J Clin Endocrinol Metab. 1995. |
| Postpartum women (1998)Clinical trial · Randomized, placebo-controlled endocrine study | 10 nonpregnant women and 58 women early or late after delivery | 100 mcg | Intravenous bolus | Single dose | Acute | Growth hormone responses in all groups, lower and slower with lactation and higher prolactin | Postpartum hyperprolactinemia and hyporesponsiveness of growth hormone (GH) to GH-releasing peptide. J Clin Endocrinol Metab. 1998. |
| Routes and kinetics of GHRPs (1993)Research-reported · Human pharmacology report covering GHRP-6, GHRP-1 and GHRP-2 | Normal younger men and/or women (n not stated in the indexed abstract) | Not stated in the indexed abstract for GHRP-1, except 1 mcg/kg intravenously with GHRH | Intravenous, subcutaneous and oral routes were studied across the GHRPs | Not stated in the indexed abstract | Not stated in the indexed abstract | Growth hormone was released by each route; GHRP-1 and GHRP-2 released near-maximal growth hormone after oral dosing | GH releasing peptides--structure and kinetics. J Pediatr Endocrinol. 1993. |
Where sources disagree
- Several early human papers call the hexapeptide GHRP-6 simply "GHRP". Those studies, including oral and prolonged-infusion work in normal men, are evidence about GHRP-6, not GHRP-1. See the GHRP-6 profile.
- A single intravenous dose used to test the pituitary is not evidence for a repeated or subcutaneous regimen.
Sequence & molecular data
| Molecular formula | C51H62N12O7 |
|---|---|
| Molecular weight | 955.1 g/mol |
| CAS number | 141925-59-9 |
| PubChem CID | 10350910 |
| FDA UNII | 39EVI31P0W |
| ChEMBL | CHEMBL427926 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
GHRP-1 is a synthetic enkephalin-derived peptide that binds the growth hormone secretagogue receptor 1a on pituitary somatotrophs and hypothalamic neurons, the receptor for ghrelin. Activation stimulates pulsatile growth hormone release through a pathway distinct from and synergistic with growth hormone-releasing hormone. Selectivity for GH over cortisol and prolactin is lower than that of ipamorelin.
Studies
- Postpartum hyperprolactinemia and hyporesponsiveness of growth hormone (GH) to GH-releasing peptide
- Growth hormone (GH) responses to GH-releasing peptide and to GH-releasing hormone in GH-deficient children
- Effect of growth hormone-releasing peptide 1-6 on GH secretion-stimulated by GHRH and pyridostigmine in lambs
- In vivo effects of the GH-releasing heptapeptide GHRP-1 in lambs
- GH releasing peptides--structure and kinetics
Research statistics
28 PubMed publications · 28.6% human clinical research · 1 registered trial
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
GHRP-1 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Research status | Research-only compound; no approval pathway listed |
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
—
GHRP-1 side effects
No side effects listed yet for this entry.
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
GHRP-1: frequently asked questions
What is GHRP-1?
Synthetic hexapeptide growth hormone secretagogue from the same series as GHRP-2 and GHRP-6. Not FDA-approved and less studied than either. Human pharmacokinetic data is limited.
How does GHRP-1 work?
GHRP-1 is a synthetic enkephalin-derived peptide that binds the growth hormone secretagogue receptor 1a on pituitary somatotrophs and hypothalamic neurons, the receptor for ghrelin. Activation stimulates pulsatile growth hormone release through a pathway distinct from and synergistic with growth hormone-releasing hormone.
Is GHRP-1 FDA approved?
No. GHRP-1 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to GHRP-1?
Compounds most often compared with GHRP-1 include Ipamorelin, GHRP-6, Pralmorelin (GHRP-2) and Hexarelin (Examorelin). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Postpartum hyperprolactinemia and hyporesponsiveness of growth hormone (GH) to GH-releasing peptide — J Clin Endocrinol Metab, 1998External reference
- Growth hormone (GH) responses to GH-releasing peptide and to GH-releasing hormone in GH-deficient children — J Clin Endocrinol Metab, 1995External reference
- Effect of growth hormone-releasing peptide 1-6 on GH secretion-stimulated by GHRH and pyridostigmine in lambs — J Physiol Biochem, 1998External reference
- In vivo effects of the GH-releasing heptapeptide GHRP-1 in lambs — Reprod Nutr Dev, 1998External reference
- GH releasing peptides--structure and kinetics — J Pediatr Endocrinol, 1993External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 4
This GHRP-1 profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track GHRP-1 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →